FDA专家小组支持Grail的Galleri检测。但该业务所依赖的Medicare资金远未得到保证。在Grail实验室中准备处理的Galleri检测样本。Grail公司在人工智能和基因测序时代，我们仍然只能逐个器官地发现癌症。只有少数几种癌症有检测手段。
An FDA panel backed Grail’s Galleri test. But the Medicare money the business depends on is far from guaranteed. Galleri test samples being prepared for processing in a Grail lab. Grail Inc. In the age of AI and gene sequencing, we still catch cancer one organ at a time. Only a handful of cancers have any test at all.
一种能够一次性筛查数十种癌症的血液检测将是一个重大飞跃。上周，这一前景更近了一步，因为美国食品药品监督管理局的一个顾问小组支持了Grail的Galleri多癌种检测。
A blood test that could screen for dozens of cancers at once would be a major leap. Last week, that prospect moved closer when a Food and Drug Administration advisory panel backed Grail’s Galleri multi-cancer test.